Alex Shlyankevich
Directeur/Membre du Conseil chez Vision Technologies Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Michael Frid | M | 52 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 ans |
Stanislav Karpenko | M | - |
Vision Technologies Ltd.
Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | 10 ans |
Maria Vilenchik | M | 55 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 ans |
Arthur T. Healey | M | 63 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 3 ans |
Douglas H. Altschuler | M | - |
NupulseCV, Inc.
NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Yuriy Gankin | M | 58 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 ans |
Piotr Imielski | M | - |
Vision Technologies Ltd.
Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | 10 ans |
Elodie Draperi | F | - |
Vision Technologies Ltd.
Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | 10 ans |
Richard Sherman | M | - |
NupulseCV, Inc.
NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Kip Kokinakis | M | - |
Vision Technologies Ltd.
Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | - |
Greg Scott | M | - |
NupulseCV, Inc.
NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Brian Novack | M | - |
NupulseCV, Inc.
NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Douglas Moore | M | 67 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 2 ans |
Dirk Simmons | M | - |
NupulseCV, Inc.
NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Sonna Patel-Raman | F | - |
NupulseCV, Inc.
NupulseCV, Inc. Medical SpecialtiesHealth Technology NupulseCV, Inc. operates as a medical device company that develops technology to treat patients with heart failure. Its device which requires a minimally invasive surgery provides patients an alternative to medical therapy. The firm maintains strategic and financial partnership with heart failure companies around the world. The company was founded in 2010 and is headquartered in Raleigh, NC. | - |
Robert Marc Clement | M | 71 |
Vision Technologies Ltd.
Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | - |
Marc Duey | M | 68 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 10 ans |
Soulaiman Itani | M | - |
Vision Technologies Ltd.
Vision Technologies Ltd. Packaged SoftwareTechnology Services Vision Technologies Ltd. develops software for wearable devices that has the potential to transform the lives of blind and visually impaired. The company was founded by Stanislav Karpenko in June 2014 and is headquartered in London, the United Kingdom. | - |
Thomas Hughes | M | 64 |
Constant Therapeutics LLC
| 1 ans |
Michael Kody | M | - |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Valeria Povolotsky | M | - |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 15 | 71,43% |
Royaume-Uni | 6 | 28,57% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Alex Shlyankevich
- Réseau Personnel